NUTRIBAND INC.

ORLANDO, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the appointment of Robert J. O'Neill to its Advisory Board. O'Neill is a highly decorated former U.S. Navy SEAL, New York Times best-selling author, and nationally recognized speaker on leadership and resilience. O'Neill served 16 years in the U.S. Navy, including eight years with the Naval Special Warfare Development Group (SEAL Team Six), and took part in more than 400 combat...

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants. Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW...

ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The Summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking at Nasdaq MarketSite in New York. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology...

Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval. ORLANDO, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of...

ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26th as part of the CEO spotlight event. The Georgia Life Sciences Summit brings together leaders from across biotechnology, medical technology, research, manufacturing, and investment to showcase Georgia's emergence as a national leader in life sciences innovation. The Summit...

Nutriband’s Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens, Amazon.com, Inc., Cardinal Health and Other Major National Retailers ORLANDO, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) and its wholly owned subsidiary Active Intelligence (“Active Intelligence” or the “Company”), an emerging leader in innovative wellness,...

Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development. ORLANDO, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal...

The Company recently announced an exclusive distribution agreement with Innomedica CCB S.A. for its Kinesiology Line, AVERSA products and Mosquito repellent patches ORLANDO, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that The Costa Rica Ministry of Health has approved the Company’s line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company’s exclusive distribution partner for Costa Rica oversaw and financed the...

ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch. About AVERSA™ Abuse-Deterrent...